Scott analyzes the implications of the FDA ending compounded GLP-1 weight loss drugs, which have provided a cheaper alternative to official channels for the past three years, and examines various responses from both compounding pharmacies and pharmaceutical companies.

Scott Alexander examines how compounding pharmacies are producing cheaper versions of GLP-1 agonist drugs, exploring the economics, safety, and future implications of this practice.

Scott Alexander summarizes and responds to comments on his post about semaglutide, covering corrections, additional information, and user experiences with the weight loss drug.

Scott Alexander analyzes the economic and societal implications of semaglutide, a new effective weight loss drug, and its potential to reshape obesity treatment.

Scott Alexander highlights and responds to expert comments on his previous posts about Zulresso and Zuranolone, covering various aspects of these drugs and related topics.

Scott Alexander examines Zulresso and Zuranolone, two neurosteroid drugs for postpartum depression, discussing their efficacy, challenges, and potential future applications.

Scott Alexander compiles reader comments on healthcare systems in various countries, discussing economics, drug pricing, and personal experiences.

Scott Alexander reviews a book comparing international healthcare systems, finding it informative but lacking in explaining why some systems succeed while others fail.

Scott Alexander critiques the FDA approval of esketamine for depression, discussing issues with drug development, efficacy, cost, and administration requirements.

Scott argues against Vox's proposal for drug price controls, citing studies that such policies would significantly reduce pharmaceutical innovation and potentially cost millions of life-years long-term.

The post examines three major issues with generic medications: barriers to market entry, problematic FDA initiatives, and inconsistent pricing across pharmacies.